BAUSCH AND LOMB
SpecialtyBAUSCH AND LOMB is a specialty pharmaceutical company focused on Ophthalmology, Cardiovascular, Infectious Disease. Key products include PROLENSA.
FDA Novel Drug Designations
(2016-2023)BAUSCH AND LOMB's Key Drugs
BAUSCH AND LOMB's core commercial portfolio centers on LOTEMAX SM, XIPERE, PROLENSA, spanning Ophthalmology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Inflammation
Macular Edema
Inflammation
Open-Angle Glaucoma
Dry Eye Disease
BAUSCH AND LOMB's Recent FDA Approvals
New NDA/BLA approvals for BAUSCH AND LOMB over the last two years — novel drugs only, excluding generics and label supplements.
BAUSCH AND LOMB's Therapeutic Areas
BAUSCH AND LOMB's approved drugs and pipeline span 5 therapeutic areas, led by Ophthalmology and Cardiovascular, across 0 biologic and 23 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BAUSCH AND LOMB's Top Competitors
BAUSCH AND LOMB's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, BAUSCH, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BAUSCH AND LOMB Pipeline Snapshot
Active clinical trials for BAUSCH AND LOMB across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (8)
Discontinued (0)
Company Info
- First Approval
- 1978-08-17
- Latest
- 2026-01-20
- Applications
- 84